FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367018599> ?p ?o ?g. }

• W4367018599 abstract "Introduction Recent studies have shown beneficial effects of Carotid artery stenting (CAS) in acute ischemic stroke patients with tandem lesions (TL). However, stent placement requires the use of antiplatelet medications to prevent in‐stent thrombosis and re‐occlusion of the artery. This must be balanced with the risk of intracerebral hemorrhage. In this multicenter study, we aimed to investigate the safety and feasibility of using antiplatelet regimens in patients with anterior circulation stroke with TLs. Methods Patient level data were pooled from 17 centers and included patients with intracranial occlusion of ICA or M1/M2 segment of MCA with a concomitant extracranial ICA occlusion or stenosis ≥ 50%. Inclusion criteria were; age ≥ 18 years, EVT for intracranial occlusion, and underwent treatment for extracranial ICA lesions demonstrated on CTA and/or DSA. Patients were divided into groups according to the number of antiplatelets administered at the time of endovascular therapy (EVT) procedure into four groups including; 1) no antiplatelets, 2) single oral antiplatelet, 3) dual antiplatelets, and 4) intravenous antiplatelets (in combination of single or dual antiplatelets). Multivariable logistic regression models with multiple imputations were built to assess the association of primary outcome; symptomatic intracranial hemorrhage (sICH), and secondary outcomes including; modified Rankin Score (mRS) 0–2 at 90 days, and successful reperfusion (mTICI score ≥ 2b). Results A total of 682 patients were included. Of these, 138 (20.2%) did not receive any antiplatelet therapy, while 143 (20.97%) were treated with single oral, 207 (30.35%) with dual oral, and 194 (28.5%) with intravenous combined with single or dual antiplatelets. The rate of favorable outcome was non‐significantly higher in the dual (53%) and IV‐combination (54.4%) antiplatelets, as compared with single (38.9%) and without antiplatelet (38.6%) medications. In the multivariable model, after adjusting, there was no significant differences in the sICH (single: aOR: 1.07, CI: 0.62‐1.84, p = 0.8, dual: aOR: 1.18, CI: 0.70‐1.99, p = 0.55, IV‐combination: aOR: 1.01, CI: 0.57‐1.78, p = 0.98) and functional outcome at 90 days (single: aOR: 1.15, CI: 0.63‐2.12, p = 0.64, dual: aOR: 1.03, CI: 0.55‐1.9, p = 0.9, IV‐combination: aOR: 0.83, CI: 0.42‐1.64, p = 0.59) among the study groups. Interestingly, successful reperfusion (mTICI score ≥ 2b) was significantly higher in dual oral and IV‐combination antiplatelets (single: aOR: 1.14, CI: 0.61‐2.14, p = 0.69, dual: aOR: 4.82, CI: 2.23‐10.42, p = < 0.001, IV‐combination: aOR: 3.65, CI: 1.71‐7.79, p = 0.001). Conclusions Administration of antiplatelet medications during EVT was associated with successful reperfusion without increasing the rate of symptomatic hemorrhage in patients with anterior circulation LVO with TLs. Further large‐scale randomized studies are warranted to validate the optimal antiplatelet regimens during acute carotid artery stenting in patients with TLs." @default.
• W4367018599 created "2023-04-27" @default.
• W4367018599 creator A5000212230 @default.
• W4367018599 creator A5000410497 @default.
• W4367018599 creator A5001593915 @default.
• W4367018599 creator A5006164143 @default.
• W4367018599 creator A5006733279 @default.
• W4367018599 creator A5008384414 @default.
• W4367018599 creator A5010436728 @default.
• W4367018599 creator A5016302815 @default.
• W4367018599 creator A5019945636 @default.
• W4367018599 creator A5021747058 @default.
• W4367018599 creator A5023340417 @default.
• W4367018599 creator A5023839322 @default.
• W4367018599 creator A5025054170 @default.
• W4367018599 creator A5026314299 @default.
• W4367018599 creator A5026837827 @default.
• W4367018599 creator A5028685996 @default.
• W4367018599 creator A5028823209 @default.
• W4367018599 creator A5030172137 @default.
• W4367018599 creator A5031762120 @default.
• W4367018599 creator A5031951334 @default.
• W4367018599 creator A5033405400 @default.
• W4367018599 creator A5034282536 @default.
• W4367018599 creator A5037230305 @default.
• W4367018599 creator A5038040555 @default.
• W4367018599 creator A5042426475 @default.
• W4367018599 creator A5043300449 @default.
• W4367018599 creator A5044156349 @default.
• W4367018599 creator A5047977472 @default.
• W4367018599 creator A5051334387 @default.
• W4367018599 creator A5052829401 @default.
• W4367018599 creator A5056209075 @default.
• W4367018599 creator A5058681430 @default.
• W4367018599 creator A5065390752 @default.
• W4367018599 creator A5066286495 @default.
• W4367018599 creator A5067250692 @default.
• W4367018599 creator A5067350514 @default.
• W4367018599 creator A5069676207 @default.
• W4367018599 creator A5078791960 @default.
• W4367018599 creator A5079146238 @default.
• W4367018599 creator A5082559418 @default.
• W4367018599 creator A5084031864 @default.
• W4367018599 creator A5086388266 @default.
• W4367018599 creator A5086573802 @default.
• W4367018599 creator A5088699436 @default.
• W4367018599 creator A5090629416 @default.
• W4367018599 date "2023-03-01" @default.
• W4367018599 modified "2023-10-16" @default.
• W4367018599 title "Abstract Number ‐ 157: Effect of Antiplatelet Therapy in Acute Ischemic Stroke with Tandem Lesions" @default.
• W4367018599 doi "https://doi.org/10.1161/svin.03.suppl_1.157" @default.
• W4367018599 hasPublicationYear "2023" @default.
• W4367018599 type Work @default.
• W4367018599 citedByCount "0" @default.
• W4367018599 crossrefType "journal-article" @default.
• W4367018599 hasAuthorship W4367018599A5000212230 @default.
• W4367018599 hasAuthorship W4367018599A5000410497 @default.
• W4367018599 hasAuthorship W4367018599A5001593915 @default.
• W4367018599 hasAuthorship W4367018599A5006164143 @default.
• W4367018599 hasAuthorship W4367018599A5006733279 @default.
• W4367018599 hasAuthorship W4367018599A5008384414 @default.
• W4367018599 hasAuthorship W4367018599A5010436728 @default.
• W4367018599 hasAuthorship W4367018599A5016302815 @default.
• W4367018599 hasAuthorship W4367018599A5019945636 @default.
• W4367018599 hasAuthorship W4367018599A5021747058 @default.
• W4367018599 hasAuthorship W4367018599A5023340417 @default.
• W4367018599 hasAuthorship W4367018599A5023839322 @default.
• W4367018599 hasAuthorship W4367018599A5025054170 @default.
• W4367018599 hasAuthorship W4367018599A5026314299 @default.
• W4367018599 hasAuthorship W4367018599A5026837827 @default.
• W4367018599 hasAuthorship W4367018599A5028685996 @default.
• W4367018599 hasAuthorship W4367018599A5028823209 @default.
• W4367018599 hasAuthorship W4367018599A5030172137 @default.
• W4367018599 hasAuthorship W4367018599A5031762120 @default.
• W4367018599 hasAuthorship W4367018599A5031951334 @default.
• W4367018599 hasAuthorship W4367018599A5033405400 @default.
• W4367018599 hasAuthorship W4367018599A5034282536 @default.
• W4367018599 hasAuthorship W4367018599A5037230305 @default.
• W4367018599 hasAuthorship W4367018599A5038040555 @default.
• W4367018599 hasAuthorship W4367018599A5042426475 @default.
• W4367018599 hasAuthorship W4367018599A5043300449 @default.
• W4367018599 hasAuthorship W4367018599A5044156349 @default.
• W4367018599 hasAuthorship W4367018599A5047977472 @default.
• W4367018599 hasAuthorship W4367018599A5051334387 @default.
• W4367018599 hasAuthorship W4367018599A5052829401 @default.
• W4367018599 hasAuthorship W4367018599A5056209075 @default.
• W4367018599 hasAuthorship W4367018599A5058681430 @default.
• W4367018599 hasAuthorship W4367018599A5065390752 @default.
• W4367018599 hasAuthorship W4367018599A5066286495 @default.
• W4367018599 hasAuthorship W4367018599A5067250692 @default.
• W4367018599 hasAuthorship W4367018599A5067350514 @default.
• W4367018599 hasAuthorship W4367018599A5069676207 @default.
• W4367018599 hasAuthorship W4367018599A5078791960 @default.
• W4367018599 hasAuthorship W4367018599A5079146238 @default.
• W4367018599 hasAuthorship W4367018599A5082559418 @default.
• W4367018599 hasAuthorship W4367018599A5084031864 @default.
• W4367018599 hasAuthorship W4367018599A5086388266 @default.
• W4367018599 hasAuthorship W4367018599A5086573802 @default.
• W4367018599 hasAuthorship W4367018599A5088699436 @default.
• W4367018599 hasAuthorship W4367018599A5090629416 @default.

• next